A randomised phase II study comparing LEnalidomide plus rituximab, GEmcitabine and methylprednisolone (LR-GEM) to rituximab, gemcitabine, methylprednisolone and cisplatiN (R-GEM-P) in second-line treatment of Diffuse Large B-cell lymphoma (DLBCL)

Trial Profile

A randomised phase II study comparing LEnalidomide plus rituximab, GEmcitabine and methylprednisolone (LR-GEM) to rituximab, gemcitabine, methylprednisolone and cisplatiN (R-GEM-P) in second-line treatment of Diffuse Large B-cell lymphoma (DLBCL)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Lenalidomide (Primary) ; Cisplatin; Gemcitabine; Methylprednisolone; Rituximab
  • Indications Diffuse large B cell lymphoma
  • Focus Therapeutic Use
  • Acronyms LEGEND
  • Most Recent Events

    • 22 Nov 2015 Accrual to date is 22% according to United Kingdom Clinical Research Network.
    • 08 Oct 2015 Accrual to date is 22% according to United Kingdom Clinical Research Network.
    • 16 Sep 2015 Accrual to date is 21% according to United Kingdom Clinical Research Network.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top